Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Tumor-Agnostic 1Head & Neck 1

Conditions

Neoplasms 22Neoplasm Metastasis 10Neoplasms, Unknown Primary 3Carcinoma, Squamous Cell 3Carcinoma 1Adenocarcinoma 1

Interventions

Paclitaxel 9Carboplatin 9pembrolizumab 7Radiotherapy 7Cisplatin 5Axitinib 4Pemetrexed 3Nivolumab 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2fludarabine 2dacomitinib 2catumaxomab 2Trastuzumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Nurses 2Interleukin-2 2Gemcitabine 2Docetaxel 2Cyclophosphamide 2Cetuximab 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vatalanib 1temsirolimus 1sovateltide 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Erlotinib Hydrochloride × Tumor-Agnostic × Clear all
NCT00737243 2016-08-17

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 2 Completed
289 enrolled 5 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡